美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Silexion Therapeutics Corp

1.34

+0.07005.51%

盤後：1.32-0.0200-1.49%19:17 EDT

成交量：21.68萬

成交額：28.41萬

市值：446.33萬

市盈率：-0.15

高：1.36

開：1.26

低：1.07

收：1.27

52周最高：22.36

52周最低：1.07

股本：333.08萬

流通股本：299.54萬

量比：6.42

換手率：7.24%

股息：- -

股息率：- -

每股收益(TTM):-8.9597

每股收益(LYR):-395.3595

淨資產收益率：-771.23%

總資產收益率：-144.27%

市淨率：1.71

市盈率(LYR):0.00

資料載入中...

總覽公司新聞資訊公告

Silexion Therapeutics計劃本季度末在德國提交2/3期臨床試驗申請，並擬於2027年初在歐盟提交額外監管申請

Silexion Therapeutics獲以色列衞生部批准啓動Sil204治療局部晚期胰腺癌的2/3期臨床試驗

Silexion Therapeutics公布2025年第四季度及全年財務業績並更新業務進展

Silexion Therapeutics Corp盤中異動大幅下挫5.14%報1.66美元

Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨床試驗設計的積極反饋

Silexion Therapeutics 成功完成 Sil204 的毒理學研究，為胰腺癌的 2/3 階段臨床試驗做好準備

Silexion Therapeutics Corp公布積極的人體細胞係數據，證實Sil204的泛KRAS活性，抑制率高達99.7%，並首次在胃癌中顯示療效

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SLXN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.34,"timestamp":1774382400000,"preClose":1.27,"halted":0,"volume":216818,"hourTrading":{"tag":"盘后","latestPrice":1.32,"preClose":1.34,"latestTime":"19:17 EDT","volume":165,"amount":220.87,"timestamp":1774394242504,"change":-0.02,"changeRate":-0.014925,"amplitude":0.014925},"delay":0,"changeRate":0.05511811023622052,"floatShares":2995400,"shares":3330800,"eps":-8.959658,"marketStatus":"已收盤","change":0.07,"latestTime":"03-24 16:00:00 EDT","open":1.26,"high":1.355,"low":1.07,"amount":284096.842218,"amplitude":0.224409,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-8.959658,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774425600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.27,"preHourTrading":{"tag":"盘前","latestPrice":1.25,"preClose":1.27,"latestTime":"09:29 EDT","volume":44695,"amount":60001.7994485,"timestamp":1774358941017,"change":-0.02,"changeRate":-0.015748,"amplitude":0.204724},"postHourTrading":{"tag":"盘后","latestPrice":1.32,"preClose":1.34,"latestTime":"19:17 EDT","volume":165,"amount":220.87,"timestamp":1774394242504,"change":-0.02,"changeRate":-0.014925,"amplitude":0.014925},"volumeRatio":6.41629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":2995400,"roa":"-144.27%","roe":"-771.23%","lyrEps":-395.359461,"volumeRatio":6.41629,"shares":3330800,"dividePrice":0,"high":1.355,"amplitude":0.224409,"preClose":1.27,"low":1.07,"week52Low":1.07,"pbRate":"1.71","week52High":22.36,"institutionHeld":0,"latestPrice":1.34,"eps":-8.959658,"divideRate":0,"volume":216818,"delay":0,"ttmEps":-8.959658,"open":1.26,"prevYearClose":1.92,"prevWeekClose":1.22,"prevMonthClose":1.725,"prevQuarterClose":1.92,"fiveDayClose":1.56,"twentyDayClose":1.5,"sixtyDayClose":2.36},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1765857600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-03-23","current":-0.149559,"percent":0.623894,"low":-1.070842,"twenty":-0.587662,"median":-0.432424,"eighty":-0.128686,"high":-0.075397,"avg":-0.418218,"sd":0.242466,"marketCap":3814503},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094},{"date":"2026-02-27","current":-0.588338,"twenty":-0.588338,"median":-0.42265,"eighty":-0.127254,"marketCap":5440357},{"date":"2026-03-06","current":-0.557906,"twenty":-0.584956,"median":-0.42723,"eighty":-0.127936,"marketCap":5158959},{"date":"2026-03-13","current":-0.563418,"twenty":-0.591719,"median":-0.432424,"eighty":-0.128618,"marketCap":5209923},{"date":"2026-03-20","current":-0.377654,"twenty":-0.588338,"median":-0.436237,"eighty":-0.128618,"marketCap":4498612},{"date":"2026-03-23","current":-0.320224,"twenty":-0.587662,"median":-0.432424,"eighty":-0.128686,"marketCap":3814503}],"updateTime":1774395326057},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1128273196","title":"Silexion Therapeutics計劃本季度末在德國提交2/3期臨床試驗申請，並擬於2027年初在歐盟提交額外監管申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1128273196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128273196?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:39","pubTimestamp":1774355952,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布，计划在本季度末前向德国监管机构提交其2/3期临床试验的申请。此外，公司还预计将在2027年初于欧盟范围内提交额外的监管申请文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1158550340","title":"Silexion Therapeutics獲以色列衞生部批准 啓動Sil204治療局部晚期胰腺癌的2/3期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158550340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158550340?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:38","pubTimestamp":1774355925,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp已正式获得以色列卫生部批准，将启动其核心候选药物Sil204针对局部晚期胰腺癌的2/3期临床试验。这一关键监管许可标志着该药物临床开发进程中的重要一步，为评估其在治疗这一难治性癌症方面的潜力铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1112627847","title":"Silexion Therapeutics公布2025年第四季度及全年財務業績並更新業務進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1112627847","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112627847?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 05:02","pubTimestamp":1773781344,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp公布了2025年第四季度及全年的财务业绩，并同步更新了公司最新的业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"2610620679","title":"Silexion Therapeutics Corp盤中異動 大幅下挫5.14%報1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610620679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610620679?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 01:34","pubTimestamp":1770744859,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日01时34分，Silexion Therapeutics Corp股票出现波动，股价急速下挫5.14%。截至发稿，该股报1.66美元/股，成交量2.9551万股，换手率0.95%，振幅6.86%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体涨幅为0.14%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp 是一家临床阶段的肿瘤学生物技术公司，致力于发现和开发KRAS驱动癌症的专有治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","BK4539","SLXN","LENZ"],"gpt_icon":0},{"id":"1108369243","title":"Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨床試驗設計的積極反饋","url":"https://stock-news.laohu8.com/highlight/detail?id=1108369243","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108369243?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 21:01","pubTimestamp":1764680504,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics获得德国卫生部门对其胰腺癌2/3期临床试验设计的积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1186776790","title":"Silexion Therapeutics 成功完成 Sil204 的毒理學研究，為胰腺癌的 2/3 階段臨床試驗做好準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1186776790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186776790?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080200,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 成功完成了 Sil204 的毒理学研究，这是一种下一代 RNA 静默疗法，为即将进行的胰腺癌 2/3 阶段临床试验做好了准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0},{"id":"1183341465","title":"Silexion Therapeutics Corp公布積極的人體細胞係數據，證實Sil204的泛KRAS活性，抑制率高達99.7%，並首次在胃癌中顯示療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1183341465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183341465?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236051,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布公布积极的人体细胞系新数据，证实了其候选药物Sil204的泛KRAS活性。数据显示，该药物的抑制率高达99.7%，并首次在胃癌治疗中展现出积极效果。\n这项最新研究结果进一步验证了Sil204作为泛KRAS抑制剂的潜力，为该公司在肿瘤治疗领域的药物开发提供了重要支撑。特别值得关注的是，这是该药物首次在胃癌细胞中显示出治疗活性，为胃癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}